The Role of Gut Microbiota in Neurodegenerative Diseases: A Systematic Review and Meta-Analysis
Authors
Jane A. Doe1, John B. Smith2, Emily C. Johnson1,3
1Department of Neuroscience, University of Example, City, State, ZIP, Country
2Department of Microbiology, University of Example, City, State, ZIP, Country
3Center for Gut-Brain Research, University of Example, City, State, ZIP, Country
Corresponding Author
Jane A. Doe, Email: jane.doe@example.edu
Abstract
Background: Emerging evidence suggests a link between gut microbiota dysbiosis and neurodegenerative diseases (NDDs) such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). This systematic review and meta-analysis evaluates the association between gut microbiota composition and NDD risk.
Methods: We searched PubMed, Embase, and Web of Science up to March 2023 for observational studies comparing gut microbiota in NDD patients versus controls. Random-effects meta-analysis was performed to pool odds ratios (ORs) and standardized mean differences (SMDs).
Results: Thirty-two studies (n=4,512 participants) were included. NDD patients showed reduced Bifidobacterium (SMD = -1.24, 95% CI: -1.67 to -0.81) and increased Proteobacteria (SMD = 0.89, 95% CI: 0.45 to 1.33). Meta-regression indicated disease severity moderated effects (p=0.012).
Conclusions: Gut microbiota alterations are consistently associated with NDDs, supporting the microbiota-gut-brain axis hypothesis. Future RCTs targeting microbiota modulation are warranted.
Keywords: Gut microbiota, Neurodegenerative diseases, Microbiome, Meta-analysis, Gut-brain axis
Introduction
Neurodegenerative diseases (NDDs) represent a growing global health burden, affecting over 50 million people worldwide (World Health Organization, 2023). Pathological hallmarks include protein aggregation and neuroinflammation, but etiology remains multifactorial. Recent research implicates the gut microbiota—the trillions of microorganisms in the gastrointestinal tract—in modulating brain health via the microbiota-gut-brain axis (Cryan et al., 2019).
Dysbiosis, or imbalance in microbial communities, has been observed in AD, PD, and ALS, potentially driving neuroinflammation through microbial metabolites like short-chain fatty acids (SCFAs) and lipopolysaccharides (LPS) (Devlin et al., 2022). Animal models demonstrate that fecal microbiota transplantation from PD patients induces motor deficits in germ-free mice (Sampson et al., 2016). However, human studies are heterogeneous, necessitating systematic synthesis.
This review aims to: (1) quantify microbiota differences in NDD patients versus controls; (2) explore heterogeneity sources; and (3) assess implications for therapeutics.
Methods
Search Strategy and Selection Criteria
This systematic review followed PRISMA guidelines (Page et al., 2021). We searched PubMed, Embase, and Web of Science from inception to March 31, 2023, using terms: (“gut microbiota” OR “gut microbiome”) AND (“Alzheimer” OR “Parkinson” OR “amyotrophic lateral sclerosis” OR “neurodegenerative”). No language restrictions applied. Two reviewers independently screened titles/abstracts and full texts, resolving discrepancies by consensus.
Inclusion: observational studies (case-control, cohort) reporting microbiota composition (16S rRNA or shotgun sequencing) in NDD patients (diagnosed per standard criteria) versus healthy controls. Exclusion: animal studies, reviews, <20 participants/group.
Data Extraction and Quality Assessment
Extracted data included: study characteristics, participant demographics, sequencing method, alpha/beta diversity metrics, and taxon abundances (phylum/genus level). Risk of bias was assessed using ROBINS-I (Sterne et al., 2016). Newcastle-Ottawa Scale was used for cohort studies.
Statistical Analysis
Random-effects meta-analyses pooled standardized mean differences (SMDs) for continuous outcomes (e.g., relative abundance) and odds ratios (ORs) for categorical dysbiosis definitions, using inverse-variance weighting. Heterogeneity was quantified by I2. Subgroup analyses stratified by NDD type, sequencing method, and geography. Meta-regression examined moderators (age, disease duration). Publication bias was assessed via Egger’s test and funnel plots. Analyses conducted in R (version 4.2.1) with metafor package.
Results
Study Characteristics
Database searches yielded 1,247 records; 32 studies met criteria (Figure 1: PRISMA flow diagram). Total participants: 2,156 NDD patients, 2,356 controls. Most studies focused on PD (n=18), followed by AD (n=10) and ALS (n=4). Sequencing: 16S rRNA (n=25), shotgun (n=7). Mean quality score: 7.2/9 (Table 1).
Alpha Diversity
NDD patients exhibited lower Shannon index (SMD = -0.62, 95% CI: -0.89 to -0.35, I2=78%, 28 studies; Figure 2).
Taxonomic Composition
| Taxon | SMD (95% CI) | I2 (%) | n Studies |
|---|---|---|---|
| Firmicutes (phylum) | -0.45 (-0.72 to -0.18) | 65 | 22 |
| Bacteroidetes (phylum) | 0.31 (0.12 to 0.50) | 52 | 20 |
| Bifidobacterium (genus) | -1.24 (-1.67 to -0.81) | 85 | 15 |
| Proteobacteria (phylum) | 0.89 (0.45 to 1.33) | 72 | 18 |
Table 1: Pooled SMDs for key taxa.
Subgroup and Sensitivity Analyses
Effects were robust in PD (SMD Shannon = -0.71) but less pronounced in AD (-0.48). Meta-regression showed disease duration positively associated with Proteobacteria enrichment (β=0.15, p=0.008). No publication bias (Egger’s p=0.42).
Discussion
This meta-analysis confirms gut microbiota dysbiosis in NDDs, characterized by reduced beneficial taxa (Bifidobacterium) and pathogenic overgrowth (Proteobacteria). These shifts likely promote neuroinflammation via impaired SCFA production and increased gut permeability (“leaky gut”), facilitating LPS translocation (Anderson et al., 2019).
Strengths include comprehensive search and robust statistics. Limitations: observational design precludes causality; heterogeneity from protocols; potential confounders (diet, antibiotics). Future studies should standardize methods and explore longitudinal changes.
Clinically, probiotics/prebiotics targeting dysbiosis show promise in PD trials (Tan et al., 2022). Microbiota-based diagnostics or FMT could revolutionize NDD management.
Conclusion
Gut microbiota alterations are a consistent NDD feature, underscoring therapeutic potential. Prospective studies are essential.
Acknowledgements
Funded by NIH Grant R01NS123456.
Conflicts of Interest
None declared.
References
- Anderson, G., et al. (2019). The gut microbiome and Alzheimer’s disease. Journal of Alzheimer’s Disease, 72(1), 1-15.
- Cryan, J. F., et al. (2019). The microbiota-gut-brain axis. Physiological Reviews, 99(4), 1877-2013.
- Devlin, A. S., et al. (2022). Microbial metabolites in neurodegeneration. Nature Reviews Neuroscience, 23(5), 279-295.
- Page, M. J., et al. (2021). PRISMA 2020 statement. BMJ, 372, n71.
- Sampson, T. R., et al. (2016). Gut microbiota regulate motor deficits in Parkinson’s. Cell, 167(5), 1469-1480.
- Sterne, J. A., et al. (2016). ROBINS-I tool. BMJ, 355, i4919.
- Tan, A. H., et al. (2022). Probiotics for Parkinson’s: A RCT. Lancet Neurology, 21(6), 523-533.
- World Health Organization. (2023). Dementia fact sheet. Retrieved from who.int.
